Literature DB >> 25489270

Need to minimize bias when surveying patient attitudes to stopping cml treatment.

Lucia A Villemagne-Sanchez1, David M Ross2, Penelope Schofield3.   

Abstract

Entities:  

Year:  2014        PMID： 25489270      PMCID： PMC4257127          DOI： 10.3747/co.21.2177

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  5 in total

1.  Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia.

Authors:  D Sanford; R Kyle; A Lazo-Langner; A Xenocostas; I Chin-Yee; K Howson-Jan; C Hsia
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

Review 2.  How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia.

Authors:  David M Ross; Timothy P Hughes
Journal:  Br J Haematol       Date:  2014-04-23       Impact factor: 6.998

3.  Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory.

Authors:  C S Cleeland; T R Mendoza; X S Wang; C Chou; M T Harle; M Morrissey; M C Engstrom
Journal:  Cancer       Date:  2000-10-01       Impact factor: 6.860

4.  Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study.

Authors:  Simon Wu; Desmond Chee; Anna Ugalde; Phyllis Butow; John Seymour; Penelope Schofield
Journal:  Palliat Support Care       Date:  2014-02-13

5.  Concurrent and predictive validity of a self-reported measure of medication adherence.

Authors:  D E Morisky; L W Green; D M Levine
Journal:  Med Care       Date:  1986-01       Impact factor: 2.983
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.